Dukarb L

Dukarb L (BR-A-657) is a fixed-dose triple combination therapy developed by Boryung Pharmaceutical for the treatment of essential hypertension. It combines three antihypertensive agents with complementary mechanisms of action: fimasartan, a non-peptide angiotensin II receptor blocker (ARB); amlodipine, a dihydropyridine calcium channel blocker (CCB); and indapamide, a thiazide-like diuretic. Fimasartan selectively inhibits the binding of angiotensin II to the AT1 receptor, reducing vasoconstriction and aldosterone secretion. Amlodipine inhibits the influx of calcium ions into vascular smooth muscle, leading to vasodilation. Indapamide promotes the excretion of sodium and water by inhibiting the sodium-chloride symporter in the distal convoluted tubule of the kidney. This triple combination is intended for patients whose blood pressure is not adequately controlled by dual therapy, providing a simplified dosing regimen to improve medication adherence and achieve target blood pressure levels. Dukarb L was approved by the South Korean Ministry of Food and Drug Safety (MFDS) in early 2024.

Brand names

Dukarb L

Other names

fimasartan + amlodipine + indapamide